Premium
Studies of the Dysglycemic Peptide, Pancreastatin, Using a Human Forearm Model
Author(s) -
CADMAN PETER E.,
RAO FANGWEN,
MAHATA SUSHIL K.,
O'CONNOR DANIEL T.
Publication year - 2002
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2002.tb04518.x
Subject(s) - forearm , endocrinology , brachial artery , medicine , insulin , chromogranin a , plethysmograph , hemodynamics , blood flow , blood pressure , surgery , immunohistochemistry
A bstract : The physiologic effects of the chromogranin A peptide fragment, pancreastatin, were studied in six healthy Caucasian men, ages 25‐46 years. Synthetic pancreastatin (human chromogranin A 273‐301 ‐amide) was infused into the brachial artery of each subject to achieve a local concentration of ∼200 nM over 15 minutes. Forearm blood flow was measured by strain‐gauge plethysmography while (A‐V) glucose was monitored by arterial and venous sampling. Pancreastatin infusion significantly reduced forearm glucose uptake (mean reduction ± 1 SEM, 54 ± 15%; P = 0.028 ) but did not alter forearm blood flow—indicating a metabolic, rather than hemodynamic, effect. Simultaneous infusion of pancreastatin with insulin (0.1 mU/kg/min) did not diminish insulin‐induced forearm glucose uptake, suggesting pancreastatin is not simply a negative insulin modulator. The results of this study suggest that pancreastatin may contribute to the dysglycemia associated with type 2 diabetes and essential hypertension, two common human disease states in which plasma pancreastatin levels are elevated.